NCT04729764View on ClinicalTrials.gov

Evaluation the Safety and Tolerance of GP681 Tablets in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 27, 2020

Primary Completion Date

December 15, 2020

Study Completion Date

December 15, 2020

Conditions
Influenza
Interventions
DRUG

GP681 Tablet

Designed as 5 dose groups (20mg, 40mg, 60mg, 80mg, 120mg), the starting dose group (20mg) 8 subjects (including 2 placebo), each other 10 subjects (including Placebo (2 cases), male and female.

Trial Locations (1)

200031

Shanghai Xuhui Central Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

INDUSTRY

NCT04729764 - Evaluation the Safety and Tolerance of GP681 Tablets in Healthy Subjects | Biotech Hunter | Biotech Hunter